Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis

 Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis

Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis

Shots:

  • The P-III OPERA, ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS, presented at AAN Annual Meeting
  • Results: reduction in risk of disability progression associated with exposure and lower B-cell levels & permanent disability progression; @24wks. reduction in CDP; @48wks. RMS, PPMS patients with CDP treated with Ocrevus vs switched to Ocrevus, (10.4 %, 43.7% vs 15.7%, 53.1%); @12, 24 & 52 wks. in RMS reduction in nerve cell damage, inflammation biomarker in serum and CSF
  • Ocrevus (ocrelizumab, IV) is a mAb targeting CD20+ B cells, administered every 6mos. and is approved in 85 countries including NA, SA, Eastern Europe & EU for both RMS & PPMS

Click here to read full press release/ article | Ref: Roche | Image: Tam Tam Phuong

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post